Literature DB >> 18070958

In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.

Ellie J C Goldstein1, Diane M Citron, C Vreni Merriam, Yumi A Warren, Kerin L Tyrrell, Helen T Fernandez.   

Abstract

Against 182 anaerobe and 241 aerobe strains obtained from diabetic foot infections, doripenem was the most active carbapenem against Pseudomonas aeruginosa (MIC(90), 2 microg/ml), more active than imipenem against Proteus mirabilis, and ertapenem was more active against Escherichia coli and Klebsiella spp. The MIC(50) and MIC(90) values were < or =0.125 microg/ml for methicillin-sensitive Staphylococcus aureus and all streptococci and 0.25/1 for Bacteroides fragilis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18070958      PMCID: PMC2224786          DOI: 10.1128/AAC.01128-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Diagnosis and treatment of diabetic foot infections.

Authors:  Benjamin A Lipsky; Anthony R Berendt; H Gunner Deery; John M Embil; Warren S Joseph; Adolf W Karchmer; Jack L LeFrock; Daniel P Lew; Jon T Mader; Carl Norden; James S Tan
Journal:  Clin Infect Dis       Date:  2004-09-10       Impact factor: 9.079

2.  Diabetic foot infections. Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases.

Authors:  E J Goldstein; D M Citron; C A Nesbit
Journal:  Diabetes Care       Date:  1996-06       Impact factor: 19.112

3.  In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.

Authors:  Hannah M Wexler; Adrian E Engel; Daniel Glass; Calida Li
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

4.  Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem.

Authors:  Shihomi Sakyo; Haruyoshi Tomita; Koichi Tanimoto; Shuhei Fujimoto; Yasuyoshi Ike
Journal:  J Antibiot (Tokyo)       Date:  2006-04       Impact factor: 2.649

5.  Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.

Authors:  Ronald N Jones; Helio S Sader; Thomas R Fritsche
Journal:  Diagn Microbiol Infect Dis       Date:  2005-05       Impact factor: 2.803

Review 6.  Doripenem.

Authors:  David Leif Anderson
Journal:  Drugs Today (Barc)       Date:  2006-06       Impact factor: 2.245

Review 7.  Foot infections in diabetic patients: the role of anaerobes.

Authors:  D N Gerding
Journal:  Clin Infect Dis       Date:  1995-06       Impact factor: 9.079

8.  Synthesis and modification of a novel 1 beta-methyl carbapenem antibiotic, S-4661.

Authors:  Y Iso; T Irie; T Iwaki; M Kii; Y Sendo; K Motokawa; Y Nishitani
Journal:  J Antibiot (Tokyo)       Date:  1996-05       Impact factor: 2.649

Review 9.  Doripenem: S 4661.

Authors: 
Journal:  Drugs R D       Date:  2003

10.  Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents.

Authors:  Diane M Citron; Ellie J C Goldstein; C Vreni Merriam; Benjamin A Lipsky; Murray A Abramson
Journal:  J Clin Microbiol       Date:  2007-07-03       Impact factor: 5.948

View more
  7 in total

1.  Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.

Authors:  Yangsoon Lee; Yongjung Park; Myung Sook Kim; Dongeun Yong; Seok Hoon Jeong; Kyungwon Lee; Yunsop Chong
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

Review 2.  Propionibacterium acnes: from commensal to opportunistic biofilm-associated implant pathogen.

Authors:  Yvonne Achermann; Ellie J C Goldstein; Tom Coenye; Mark E Shirtliff
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

3.  New insights in diabetic foot infection.

Authors:  Jean-Louis Richard; Albert Sotto; Jean-Philippe Lavigne
Journal:  World J Diabetes       Date:  2011-02-15

4.  Complete genome sequence and lifestyle of black-pigmented Corynebacterium aurimucosum ATCC 700975 (formerly C. nigricans CN-1) isolated from a vaginal swab of a woman with spontaneous abortion.

Authors:  Eva Trost; Susanne Götker; Jessica Schneider; Susanne Schneiker-Bekel; Rafael Szczepanowski; Alexandra Tilker; Prisca Viehoever; Walter Arnold; Thomas Bekel; Jochen Blom; Karl-Heinz Gartemann; Burkhard Linke; Alexander Goesmann; Alfred Pühler; Sanjay K Shukla; Andreas Tauch
Journal:  BMC Genomics       Date:  2010-02-05       Impact factor: 3.969

5.  In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.

Authors:  David R Snydman; Nilda V Jacobus; Laura A McDermott
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

Review 6.  Doripenem: a review of its use in the treatment of bacterial infections.

Authors:  Susan J Keam
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Characteristics of doripenem: a new broad-spectrum antibiotic.

Authors:  Francisco Alvarez-Lerma; Santiago Grau; Olivia Ferrández
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.